Navigation Links
Fate Therapeutics announces creation of small molecule platform for commercial-scale reprogramming
Date:10/18/2009

La Jolla, CA October 18, 2009 Fate Therapeutics, Inc. announced today the generation of human induced-pluripotent stem cells (iPSCs) using a combination of small molecules that significantly improves the speed and efficiency of reprogramming. The discoveries, which were made by Sheng Ding, Ph.D. under a research collaboration between Fate Therapeutics and The Scripps Research Institute (TSRI), represent a more than 200-fold improvement in reprogramming efficiency and reduce the reprogramming period to two weeks as compared to methods using only the four reprogramming factors (Oct 3/4, Sox2, Klf4 and c-Myc). This latest advancement has broad implications for the creation of "pharmaceutical grade" iPSCs, reprogrammed cells that can be produced without genetic modification at commercial scale quantity, quality and consistency and continues to bolster the leadership position of Fate Therapeutics in industrialized iPSC technology. The Company is developing minimally invasive techniques for reprogramming and differentiation and has exclusively in-licensed from TSRI and the Whitehead Institute for Biomedical Research a intellectual property portfolio related to iPSC technology dating back to November 2003.

"While recent studies have reported improved methods of reprogramming, those techniques have relied on further genetic manipulation or have not otherwise addressed a fundamental reprogramming challenge that iPSC generation is still a very slow and inefficient process and results in a heterogeneous population of cells," said Paul Grayson, president & CEO of Fate Therapeutics. "Once again, Dr. Ding and his team are the first group to clear yet another major hurdle required for the widespread commercial use of iPSCs for drug discovery and patient therapies."

The findings of Dr. Ding and his colleagues are published today in the Advanced Online edition of the scientific journal Nature Methods. As compared to using the four reprogram
'/>"/>

Contact: Cory Tromblee
ctromblee@macbiocom.com
617-571-7220
MacDougall Biomedical Communications, Inc.
Source:Eurekalert

Page: 1 2

Related biology news :

1. AACR, NCI and EORTC to host molecular targets and cancer therapeutics conference
2. Neurimmune Therapeutics Announces Advancement of Alzheimers Program into Preclinical Development
3. Amarna Therapeutics B.V. and TNO announce SVac research and development partnership
4. Continuous glucose monitoring technology -- special issue of Diabetes Technology and Therapeutics
5. NIH announces new program to develop therapeutics for rare and neglected diseases
6. Ocera Therapeutics licenses novel treatment for acute hepatic encephalopathy from UCLB
7. Tufts University professor receives IADR Pharmacology/Therapeutics/Toxicology Award
8. Acorda Therapeutics submits new drug application for Fampridine-SR in multiple sclerosis
9. A novel target for therapeutics against Staph infection
10. Bayhill Therapeutics and the Juvenile Diabetes Research Foundation announce research collaboration
11. Growing fuel and medicine: Advancing biofuels and plant-produced therapeutics
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/18/2015)... CORAL SPRINGS, Florida , March 18, 2015 ... as well as businesses, new revolutionary smart wallets and apps ... rapid pace.  Companies currently entrenched in the mobile payment industry ... ), Alibaba Group Holding Ltd. (NYSE: BABA ), ... GOOG ) and Facebook Inc. (NASDAQ: ...
(Date:3/16/2015)... HANOVER, Germany , March 16, 2015 /PRNewswire/ ... DERMALOG Identification Systems GmbH will present groundbreaking innovations ... Hanover, Germany . ... DERMALOG,s latest biometric innovation is well at ... the next generation e-gate made in ...
(Date:3/12/2015)... 12, 2015 WHEN:Tuesday, March 17, 2015 at ... http://bit.ly/1G7Os0L . SPEAKERS: , Frost & Sullivan Measurement ... http://photos.prnewswire.com/prnh/20150311/181111 Biometric companies must plan ... several different markets and industries. This is especially ... uptrend. Join Frost & Sullivan,s ...
Breaking Biology News(10 mins):Revolutionary Smart Wallet & Mobile Payment Choices Change the Game for Consumers - Company Begins Shipping Newest Digital Wallet to Customers 2Revolutionary Smart Wallet & Mobile Payment Choices Change the Game for Consumers - Company Begins Shipping Newest Digital Wallet to Customers 3Revolutionary Smart Wallet & Mobile Payment Choices Change the Game for Consumers - Company Begins Shipping Newest Digital Wallet to Customers 4Revolutionary Smart Wallet & Mobile Payment Choices Change the Game for Consumers - Company Begins Shipping Newest Digital Wallet to Customers 5Revolutionary Smart Wallet & Mobile Payment Choices Change the Game for Consumers - Company Begins Shipping Newest Digital Wallet to Customers 6DERMALOG Presents its Latest Biometric Innovations at the Hannover CeBIT Exhibition, 16 - 20 March 2015 2DERMALOG Presents its Latest Biometric Innovations at the Hannover CeBIT Exhibition, 16 - 20 March 2015 3Biometrics Key to Future Growth in Healthcare, Retail and Financial Markets 2Biometrics Key to Future Growth in Healthcare, Retail and Financial Markets 3
... developer and manufacturer of advanced molecular sensing and imaging ... that it has signed exclusive distribution deals for both ... markets covered include Australia, New Zealand, The Netherlands, ... Greece, Turkey, and Russia. The values of the ...
... for U.S. Department of Agriculture,s (USDA) Center for Veterinary Biologics ... each batch of a vaccine, the CVB has informed PETA ... with modern non-animal methods. The USDA has amended its Web ... CVB to follow the lead of Europe in adopting an ...
... newswire / - ERGONEX Pharma received one of the ... occasion of Frost & Sullivan,s ,2009 Excellence in Healthcare ... The highly competitive award was presented to ERGONEX Pharma ... impressive display of technological know-how and targeted vision. , ...
Cached Biology News:Spectros Signs New International Distribution Deals 2ERGONEX Pharma receives Frost & Sullivan's European Orphan Diseases Entrepreneurial Company Award 2009 2
(Date:3/26/2015)... 26, 2015 WriteResult, a premier provider ... from Yale University’s School of Public Health and New ... during a 4 month-long project. The goal of the ... income families with free access to fresh produce and ... health concerns like high blood pressure, diabetes and weight ...
(Date:3/25/2015)... Agnition announced today that it will be featured ... the first time at 7:30 a.m. CST March 31 ... the extremely important role soil microbes perform in crop ... Catalyst™ technology that enhances soil and plant health for ... again on April 28. , A biochemist at Agnition ...
(Date:3/25/2015)... 25, 2015 Optimal Research, LLC has been ... (ViE) Award "Best Clinical Site or Trial Network". ... has been selected as a nominee in this ViE ... "Highly Recommended" distinction in 2014. The ViE awards were ... accomplishments, and positive contributions of companies and individuals in ...
(Date:3/25/2015)... NEW YORK , March 25, 2015 /PRNewswire/ ... has commenced Factual Stock Report coverage on ... Bioceuticals (OTCQX: ATTBF; CSE: ATT): is a specialty ... subsidiaries of cultivating, licensing and marketing proprietary ingredients, ... medicinal markets in North America ...
Breaking Biology Technology:Yale and New Haven Farms Improving Patient Health with WriteResult's myPROpad™ 2Yale and New Haven Farms Improving Patient Health with WriteResult's myPROpad™ 3Agnition to be Featured In Upcoming Episode of American Farmer on RFD-TV 2Optimal Research Nominated 2015 Vaccine Industry Excellence (ViE) Award 2S&P Capital IQ Initiates Coverage on Abattis Bioceuticals Corp. in S&P Capital IQ Factual Stock Reports 2S&P Capital IQ Initiates Coverage on Abattis Bioceuticals Corp. in S&P Capital IQ Factual Stock Reports 3S&P Capital IQ Initiates Coverage on Abattis Bioceuticals Corp. in S&P Capital IQ Factual Stock Reports 4S&P Capital IQ Initiates Coverage on Abattis Bioceuticals Corp. in S&P Capital IQ Factual Stock Reports 5
... ... 2, 2009. , ... Portland, Maine (PRWEB) June 26, 2009 -- IntertechPira, in conjunction with the National Hydrogen ... conference bringing together hydrogen producers, developers and users to discuss the future of this ...
... , , , , NORCROSS, Ga., ... in providing automated instrument-reagent systems to the blood transfusion industry, ... an administrative action based on an early January 2009 inspection, ... license with respect to its Reagent Red Blood Cells and ...
... Clavis Pharma ASA (OSE:,CLAVIS) today announced that the Company ... gross proceeds through a private placement,of 10,750,000 new shares, each ... of NOK,12.00 per share (the "Private Placement"). , ... process and was,managed by Carnegie ASA and DnB NOR Markets ...
Cached Biology Technology:Industry Leaders Will Gather to Discuss the Future of the "Hydrogen Economy" in Washington DC 2Immucor Responds To FDA Notice 2Clavis Pharma Raises NOK 129 Million (USD 20 Million) in a Private Placement to Fund Further Development of its Pipeline of Novel Anticancer Drug Candidates 2Clavis Pharma Raises NOK 129 Million (USD 20 Million) in a Private Placement to Fund Further Development of its Pipeline of Novel Anticancer Drug Candidates 3Clavis Pharma Raises NOK 129 Million (USD 20 Million) in a Private Placement to Fund Further Development of its Pipeline of Novel Anticancer Drug Candidates 4Clavis Pharma Raises NOK 129 Million (USD 20 Million) in a Private Placement to Fund Further Development of its Pipeline of Novel Anticancer Drug Candidates 5
... The dsRNA Marker consists of ten double-stranded ... 300, 400, 500 and 1,000 base pairs. ... marker for determinating sizes of double-stranded RNAs. ... the dsRNA Marker is adjusted to approximately ...
... White to off-white solid. A ... and blocks the formation of N-glycosidic ... against Gram-positive bacteria, yeasts, fungi, ... functional thrombin receptors on human T-lymphoblastoid ...
... enzymes involved in matrix degradation. Of the ... exist in soluble form whereas MT-MMPs exist ... also known as MMP14, MMP15, MMP16 respectively ... to the cell surface. They have an ...
...
Biology Products: